Diagnostic value of mesothelin in pleural fluids: Comparison with CYFRA 21-1 and CEA

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Filiberti, Rosa ^a   Parodi, Stefano ^b   Libener, Roberta ^c   Ivaldi, Giovanni Paolo ^d   Canessa, Pier Aldo ^e   Ugolini, Donatella ^a,f   Bobbio, Barbara ^a   Marroni, Paola ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Institute of Electronics   (Italy)

^c C Arrigo Children's Hospital   (Italy)

^d AO Villa Scassi ^*  (Italy)

^e Ospedale San Bartolomeo   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

Diagnosis; Marker; Mesothelioma; Pleural effusion; ROC curves

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; MESOTHELIN; ANTIGEN CYFRA21.1; CARCINOEMBRYONIC ANTIGEN BINDING PROTEIN, HUMAN; CELL SURFACE RECEPTOR; CYTOKERATIN 19; DIAGNOSTIC AGENT; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COMPARATIVE STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METASTASIS; PLEURA FLUID; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; THORACOCENTESIS; BIOSYNTHESIS; CHEMISTRY; LUNG TUMOR; MALIGNANT PLEURA EFFUSION; MESOTHELIOMA; METABOLISM; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; FEMALE; GPI-LINKED PROTEINS; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 84875356282     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0543-6     Document Type: Article

References (47)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397-408.
2. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008;9:147-57.
3. Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol. 2010;38:874-9.
4. Kent M, Rice D, Flores R. Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol. 2008;9:158-70.
5. Aerts JG, Delahaye M, van der Kwast TH, Davidson B, Hoogsteden HC, van Meerbeeck JP. The high post-test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant. Diagn Cytopathol. 2006;34:523-7.
6. Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet. 2003;361:1326-30.
7. van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BA, Moons KG. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer. 2011;104:1325-33.
8. Alatas F, Alatas O, Metintas M, Colak O, Harmanci E, Demir S. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer. 2001;31:9-16.
9. Fuhrman C, Duche JC, Chouaid C, Abd Alsamad I, Atassi K, Monnet I, Tillement JP, Housset B. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem. 2000;33:405-10.
10. van den Heuvel MM, Korse CM, Bonfrer JM, Baas P. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer. 2008;59:350-4.
11. Korczynski P, Krenke R, Safianowska A, Gorska K, Abou CMB, Maskey-Warzechowska M, Kondracka A, Nasilowski J, Chazan R. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions. Eur J Med Res. 2009;14:128-33.
12. Shitrit D, Zingerman B, Shitrit AB, Shlomi D, Kramer MR. Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist. 2005;10:501-7.
13. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martín-Escribano P, Ortuño-de-Solo B, Estenoz-Alfaro J. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. Lung Cancer. 2003;40:289-94.
14. Miedouge M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyt MA, Reyre J, Carles P, Serre G. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer. 1999;81:1059-65.
15. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med. 1986;104:66-73.
16. Barak V, Goike H, Panaretakis K, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004;37:529-40.
17. Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S, Felletti R. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest. 2001;119:1138-42.
18. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362:1612-6.
19. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Soluble mesothelin-related protein: a blood test for mesothelioma. Lung Cancer. 2005;49:109-11.
20. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30:1541-9.
21. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax. 2007;62:569-76.
22. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2008;85:265-72.
23. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006;173:1155-60.
24. Hooper CE, Morley AJ, Virgo P, Harvey JE, Kahan B, Maskell NA. A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. Eur Respir J. 2013;41:18-24.
25. Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL, Lee YC. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med. 2009;180:437-44.
26. Hegmans JP, Veltman JD, Fung ET, Verch T, Glover C, Zhang F, Allard WJ, T'Jampens D, Hoogsteden HC, Lambrecht BN, Aerts J. Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. Technol Cancer Res Treat. 2009;8:323-32.
27. Light RW. Pleural effusions. Med Clin N Am. 2011;95:1055-70.
28. Sahn SA. Getting the most from pleural fluid analysis. Respirology. 2012;17:270-7.
29. Leers MP, Kleinveld HA, Scharnhorst V. Differentiating transudative from exudative pleural effusion: should we measure effusion cholesterol dehydrogenase? Clin Chem Lab Med. 2007;45:1332-8.
30. Casal RF, Eapen GA, Morice RC, Jimenez CA. Medical thoracoscopy. Curr Opin Pulm Med. 2009;15:313-20.
31. Metintas M, Ak G, Dundar E, Yildirim H, Ozkan R, Kurt E, Erginel S, Alatas F, Metintas S. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest. 2010;137:1362-8.
32. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-45.
33. Pepe MS. The statistical evaluation of medical tests for classification and prediction. Oxford: Oxford University Press; 2003.
34. Moll R, Franke WW, Schiller DL, Geiger P, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31:11-24.
35. Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, Rodríguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757-63.
36. Gu P, Huang G, Chen Y, Zhu C, Yuan J, Sheng S. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal. 2007;21:398-405.
37. Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology. 2008;13:518-27.
38. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 2008;63:35-41.
39. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007;13:5076-81.
40. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantification of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12:447-53.
41. Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, Raithel HJ, Kraus T, Brüning T. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol. 2011;85:185-92.
42. Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Cancer Invest. 2013;31:48-55.
43. Fujimoto N, Gemba K, Asano M, Wada S, Ono K, Ozaki S, Kishimoto T. Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma. Exp Ther Med. 2010;1:313-7.
44. Porcel JM. Pearls and myths in pleural fluid analysis. Respirology. 2011;16:44-52.
45. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, Rodriguez Panadero F, Sahn SA. Management of malignant pleural effusions. Eur Respir J. 2001;18:402-19.
46. Ray M, Kindler HL. Malignant pleural mesothelioma an update on biomarkers and treatment. Chest. 2009;136:888-96.
47. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003;27:1418-28.